Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.17 Consensus Price Target from Analysts

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has received a consensus rating of "Buy" from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $18.57.

A number of brokerages have weighed in on ORIC. LADENBURG THALM/SH SH began coverage on Oric Pharmaceuticals in a report on Tuesday. They issued a "buy" rating and a $15.00 target price for the company. Wedbush reiterated an "outperform" rating and issued a $20.00 target price on shares of Oric Pharmaceuticals in a report on Monday, June 23rd. Oppenheimer lowered their target price on Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and issued a $21.00 target price on shares of Oric Pharmaceuticals in a report on Monday, May 5th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Oric Pharmaceuticals in a report on Tuesday, May 6th.

Oric Pharmaceuticals Price Performance

Shares of Oric Pharmaceuticals stock traded up $0.47 during midday trading on Friday, reaching $10.90. The company had a trading volume of 856,396 shares, compared to its average volume of 789,769. The stock has a fifty day moving average price of $8.01 and a 200 day moving average price of $7.84. The firm has a market cap of $928.90 million, a PE ratio of -5.83 and a beta of 1.54. Oric Pharmaceuticals has a fifty-two week low of $3.90 and a fifty-two week high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. As a group, sell-side analysts forecast that Oric Pharmaceuticals will post -2.17 EPS for the current year.

Insider Buying and Selling

In other news, CFO Dominic Piscitelli sold 32,466 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total transaction of $340,893.00. Following the transaction, the chief financial officer directly owned 68,317 shares of the company's stock, valued at $717,328.50. This represents a 32.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Angie You bought 26,597 shares of the stock in a transaction dated Friday, June 20th. The shares were purchased at an average cost of $9.39 per share, for a total transaction of $249,745.83. Following the completion of the transaction, the director directly owned 26,597 shares of the company's stock, valued at $249,745.83. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 40,000 shares of company stock worth $416,289 over the last ninety days. 6.82% of the stock is owned by insiders.

Hedge Funds Weigh In On Oric Pharmaceuticals

A number of institutional investors have recently modified their holdings of ORIC. Invesco Ltd. raised its position in Oric Pharmaceuticals by 8.5% in the 4th quarter. Invesco Ltd. now owns 23,958 shares of the company's stock valued at $193,000 after buying an additional 1,876 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Oric Pharmaceuticals by 22.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after buying an additional 2,520 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Oric Pharmaceuticals by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock valued at $226,000 after buying an additional 3,131 shares during the last quarter. Swiss National Bank raised its position in Oric Pharmaceuticals by 5.4% in the 4th quarter. Swiss National Bank now owns 62,400 shares of the company's stock valued at $504,000 after buying an additional 3,200 shares during the last quarter. Finally, American Century Companies Inc. raised its position in Oric Pharmaceuticals by 4.4% in the 1st quarter. American Century Companies Inc. now owns 112,628 shares of the company's stock valued at $628,000 after buying an additional 4,766 shares during the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.